Latest News
Conference Coverage
Which interventions can treat cognitive fatigue?
SEATTLE – One intervention counteracted cognitive fatigability in a trial with objective outcome measures, a systematic review found.
Conference Coverage
High-efficacy DMTs may reduce depressive symptoms in MS
SEATTLE – Higher-efficacy DMTs may have antidepressive properties, possibly because of their anti-inflammatory...
Conference Coverage
Patients with MS who consider using marijuana are more likely to engage in risky behaviors
SEATTLE – Discussions of marijuana use should include discussions of health behaviors.
Conference Coverage
Mental illness in MS: ‘Follow the why’
SEATTLE - Unique challenges face physicians and patients, Dr. Laura T. Safar cautions.
Conference Coverage
Low baseline heart rate may not increase cardiac risk when starting fingolimod
SEATTLE – First-dose cardiac events with fingolimod are rare, regardless of whether first-dose observations occur in clinic or at home.
Conference Coverage
Group creates three-step algorithm for the management of MS relapse
SEATTLE – Distinguishing a multiple sclerosis relapse from a pseudorelapse is essential, according to a consensus statement.
Law & Medicine
Legal duty to nonpatients: Communicable diseases
A health care provider can sometimes be found liable to one other than his or her immediate patient, notwithstanding the absence of a provider-...
Conference Coverage
Fingolimod reduces MS disease activity, compared with glatiramer acetate
SEATTLE – In patients with relapsing multiple sclerosis, 0.5 mg/day fingolimod reduces the annualized relapse rate...
Conference Coverage
Hazardous cannabis use in MS linked to anxiety, depression
SEATTLE – But it is not clear if there is a cause-and-effect relationship.
Conference Coverage
Adherence to oral treatments for MS is poor
SEATTLE – One in three patients with MS has a lapse in oral therapy that lasts for at least 30 days, and...
Conference Coverage
Extended-release arbaclofen reduces MS-related spasticity
SEATTLE – A regimen of twice-daily, extended-release arbaclofen could reduce the adverse events associated with...